AT-130
产品说明书
 |
同义名 : | - |
| CAS号 : | 211364-06-6 | |
| 货号 : | A1487543 | |
| 分子式 : | C22H22BrN3O5 | |
| 纯度 : | 98% | |
| 分子量 : | 488.33 | |
| MDL号 : | MFCD30533282 | |
| 存储条件： |
Pure form Inert atmosphere, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | AT-130, a phenylpropenamide derivative, acts as a potent non-nucleoside inhibitor of HBV replication, effectively inhibiting viral DNA synthesis with an EC50 of 0.13 μM and showing activity against both wild-type and mutant HBVs in hepatoma cells[1][2][3]. It inhibits wild-type HBV with an IC50 of 2.4 μM, rtL180M HBV with an IC50 of 9.8 μM, and rtM204I HBV with an IC50 of 35.6 μM. When applied to HepG2 cells transduced with HBV baculovirus at concentrations ranging from 0.1 to 100 μM for 7 days, AT-130 induces a dose-dependent suppression of wild-type HBV replication. Specifically, 2.5 μM of AT-130 cuts encapsidated HBV DNA by 50% (IC50), and 18.5 μM reduces it by 90% (IC90). AT-130 is non-toxic to HepG2 or Huh-7 cells even at concentrations as high as 250 μM[1]. Moreover, AT-130, at varying concentrations from 0.005 to 50 μM, does not directly inhibit the endogenous DNA polymerase reaction of HBV in Huh 7 or HepG2 cells, indicating that its inhibition of HBV DNA replication in hepatoma cells does not affect viral DNA polymerase activity or core protein translation. Additionally, AT-130 at 2.5 and 18.5 μM does not alter total HBV RNA production but does decrease encapsidated RNA levels. It does not impact the production of core protein or nucleocapsids, nor does it affect the activity of the protein expression vector[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.05mL 0.41mL 0.20mL |
10.24mL 2.05mL 1.02mL |
20.48mL 4.10mL 2.05mL |
